TRPV1: A Novel Neuroprotective Target in Glaucoma

About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2008 - March 31, 2010
Grant ID
G2008060
Acknowledgement
Goals
This research is aimed at understanding how optic nerve fibers respond to eye pressure and whether blunting this response could prevent vision loss in glaucoma. The study will also help identify new drugs to reduce optic nerve loss in glaucoma by making its fibers insensitive to eye pressure.
Summary
Glaucoma is the leading cause of irreversible blindness worldwide and is estimated to afflict some 80 million people by 2020. Most people think of glaucoma as a disease about pressure in the eye, because high pressure is associated with the disease and lowering pressure often is helpful for slowing vision loss in glaucoma. In fact, glaucoma is irreversible because it damages the fibers of the optic nerve, which is part of the brain and therefore limited in its ability to heal. Our research is important because it is the first attempt to understand how these fibers respond to pressure in the eye and whether blunting this response could prevent vision loss in glaucoma. Our team is comprised of neurobiologists with expertise in how nerve fibers respond to pressure. Thus, our research will help identify new drugs that will reduce the loss of the optic nerve in glaucoma by making its fibers insensitive to pressure in the eye.
Related Grants
National Glaucoma Research
IOP-Related Gene Responses in the Optic Nerve Head and Trabecular Meshwork
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Diana C. Lozano, PhD
Current Organization
Oregon Health & Science University
National Glaucoma Research
Saving Sight: A Journey to Healing Without Scars
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Jennifer Fan Gaskin, MBChB, MD, FRANZCO
Current Organization
Centre for Eye Research Australia (Australia)
National Glaucoma Research
Understanding How Variants in LOXL1 Affect Pseudoexfoliation Glaucoma Risk
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Hannah Youngblood, PhD
Current Organization
Georgia Institute of Technology